Ocular Sciences Acquisition Puts Ciba, J&J/Vistakon In Cooper’s Sights
This article was originally published in The Gray Sheet
Executive Summary
Cooper Companies' planned Ocular Sciences purchase positions the firm to achieve $1 bil. in annual contact lens sales by 2007, according to CEO Thomas Bender
You may also be interested in...
Bear Stearns Healthcare Conference In Brief
Medtronic: Purchase of rapid-exchange stent-delivery technology from Johnson & Johnson is possible if the Federal Trade Commission requires J&J to sell the technology before completing its acquisition of Guidant. "Would we be interested? Yes...for the right price," Medtronic CFO Gary Ellis acknowledged at the Bear Stearns Healthcare Conference in New York Sept. 12. As conditions of approval for the acquisition, the European Commission and Canadian Competition Bureau are already requiring J&J to divest some businesses in their respective markets (1"The Gray Sheet" Sept. 5, 2005, In Brief). FTC is expected to rule on the proposed acquisition in October...
Bear Stearns Healthcare Conference In Brief
Medtronic: Purchase of rapid-exchange stent-delivery technology from Johnson & Johnson is possible if the Federal Trade Commission requires J&J to sell the technology before completing its acquisition of Guidant. "Would we be interested? Yes...for the right price," Medtronic CFO Gary Ellis acknowledged at the Bear Stearns Healthcare Conference in New York Sept. 12. As conditions of approval for the acquisition, the European Commission and Canadian Competition Bureau are already requiring J&J to divest some businesses in their respective markets (1"The Gray Sheet" Sept. 5, 2005, In Brief). FTC is expected to rule on the proposed acquisition in October...
Cooper Touts Growth Potential Of Proclear Line; Ocular Deal Nears Closure
Cooper Companies expects sales of its Proclear multifocal contact lens line to roughly double to $25 mil. in fiscal 2005